Toward further simplification of elotuzumab therapy by subcutaneous administration
暂无分享，去创建一个
S. Horiike | J. Kuroda | Y. Shimura | Tsutomu Kobayashi | Daichi Nishiyama | J. Yamaguchi | R. Isa | Saeko Kuwahara-Ota | T. Tsukamoto | Atsushi Suzuki
[1] K. Ohta,et al. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan , 2019, International Journal of Hematology.
[2] B. Bittner,et al. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities , 2018, BioDrugs.
[3] S. Singhal,et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. , 2012, Blood.